Utility of Breath-holding Test in Systemic Sclerosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-08-12

Study Completion Date

2023-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to evaluate the utility of breath-holding test as a marker of pulmonary disease severity in patients with systemic sclerosis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Investigation of Respiratory Muscle Sarcopenia in Patients with Systemic Sclerosis

NCT06598982

Systemic Sclerosis (SSc) Scleroderma

RECRUITING

Patients Diagnosed With Scleroderma: Physical Performance and Functionality

NCT07183072

Systemic Sclerosis (SSc) Scleroderma Scleroderma (Limited and Diffuse) +2 more

RECRUITING

Endothelial Biomarkers of Systemic Sclerosis-associated Pulmonary Hypertension

NCT03459716

Scleroderma Pulmonary Hypertension

UNKNOWN

Optical Coherence Tomography Imaging in Systemic Sclerosis

NCT04532151

Systemic Sclerosis Early Systemic Sclerosis Without Clinical Scleroderma and Onset < 2 Years

COMPLETED NA

Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients

NCT00377949

Systemic Sclerosis Scleroderma Pulmonary Hypertension +1 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Systemic sclerosis (SSc) is a chronic autoimmune disease of unknown etiology with high morbidity and mortality. SSc manifests by fibrosis of skin and internal organs. Although the underlying mechanisms are still subject to investigation, endothelial dysfunction and abnormal immune response are thought to contribute to vascular dysfunction and fibrosis in SSc.

Pulmonary involvement, such as pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD) is a major cause of death in SSc. Although the 6MWT is generally used for evaluating PAH and ILD, the utility in SSc is undetermined. Several investigators have found weak or moderate correlations of 6MWT in pulmonary involvement in SSc. The 6MWT is influenced by the status of all organ systems involved in exercise (pulmonary, cardiac, peripheral vascular, neuromuscular unit and muscle metabolism) as well as by specifics of test conditions. There is a pressing need for new, practical method which corroborates the current 6MWT for the evaluation of pulmonary disease severity in SSc.

Breath-holding test (BHT) is one of the most useful methods for assessing the sensitivity of peripheral chemoreflex. Recent studies have demonstrated that BHT was correlated to pulmonary function test. BHT can be safely conducted and doctors handle a medical emergency during test easily as well. Therefore, this study evaluates the utility of BHT as surrogate marker of pulmonary involvement in patients with SSc.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Systemic Sclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Systemic sclerosis group

Systemic sclerosis diagnosis according to 2013 American College of Rheumatology(ACR)/European League Against Rheumatism(EULAR) classification criteria

Group Type EXPERIMENTAL

scleroderma health assessment questionnaire (SHAQ), BHT, and 6MWT

Intervention Type OTHER

1. Participants will perform the SHAQ.
2. BHT and 6MWT will be performed in the randomized way for each participant.
3. For BHT, the participants will be told to sit comfortably on a chair, and breath normally. After 1 minute, they were required to make a maximum expiration followed by a maximum inspiration and to hold the breath as long as possible at maximum inspiratory level. This procedure was repeated three times, with 5-minute intervals between the tests.
4. 6MWT will be performed according to the ATS guidelines.
5. Information on CXR, TTE, and PFT (FVC%, DLCO%) will be obtained from the medical record if the data was obtained within 3 months. If not, the tests will be performed.
6. BHT and PFT will be followed by six months after the first breath-holding test to confirm the responsiveness.
7. Additional 30 patients with systemic sclerosis will be collected to perform the test-retest reliability of BHT.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

scleroderma health assessment questionnaire (SHAQ), BHT, and 6MWT

1. Participants will perform the SHAQ.
2. BHT and 6MWT will be performed in the randomized way for each participant.
3. For BHT, the participants will be told to sit comfortably on a chair, and breath normally. After 1 minute, they were required to make a maximum expiration followed by a maximum inspiration and to hold the breath as long as possible at maximum inspiratory level. This procedure was repeated three times, with 5-minute intervals between the tests.
4. 6MWT will be performed according to the ATS guidelines.
5. Information on CXR, TTE, and PFT (FVC%, DLCO%) will be obtained from the medical record if the data was obtained within 3 months. If not, the tests will be performed.
6. BHT and PFT will be followed by six months after the first breath-holding test to confirm the responsiveness.
7. Additional 30 patients with systemic sclerosis will be collected to perform the test-retest reliability of BHT.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* A diagnosis of systemic sclerosis according to 2013 ACR/EULAR criteria
* Must understand and voluntarily sign an informed consent form including writing consent for data protection

Exclusion Criteria

* The resting oxygen saturation by pulse oximetry \< 90% in room air
* Unstable angina or myocardial infarction during the previous month
* Patients considered unable to the breath-holding test or 6 minute walk test

Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No